Abstract P6-08-06: C-Reactive Protein Expression and Its Association with Disease Specific Survival and Disease Recurrence in ER Negative Breast Cancer Patients

2010 ◽  
Author(s):  
B Elsberger ◽  
C Tannahill ◽  
C Orange ◽  
EA Mallon ◽  
C Wilson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Cancer Patients ◽  
Disease Recurrence ◽  
Disease Specific Survival ◽  
Breast Cancer Patients ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Disease Specific

Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin

2000 ◽  
Vol 18 (3) ◽  
pp. 574-574 ◽  
Author(s):  
S. von Mensdorff-Pouilly ◽  
A.A. Verstraeten ◽  
P. Kenemans ◽  
F.G. M. Snijdewint ◽  
A. Kok ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Humoral Response ◽  
Disease Specific Survival ◽  
Breast Cancer Patients ◽  
Antibody Levels ◽  
Pretreatment Serum ◽  
Test Result ◽  
Disease Specific

PURPOSE: Polymorphic epithelial mucin (PEM or MUC1) is being studied as a vaccine substrate for the immunotherapy of patients with adenocarcinoma. The present study analyzes the incidence of naturally occurring MUC1 antibodies in early breast cancer patients and relates the presence of these antibodies in pretreatment serum to outcome of disease.MATERIALS AND METHODS: We measured immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to MUC1 with an enzyme-linked immunoassay (PEM.CIg), which uses a MUC1 triple-tandem repeat peptide conjugated to bovine serum albumin, in pretreatment serum samples obtained from 154 breast cancer patients (52 with stage I disease and 102 with stage II) and 302 controls. The median disease-specific survival time of breast cancer patients was 74 months (range, 15 to 118 months). A positive test result was defined as MUC1 IgG or IgM antibody levels equal to or greater than the corresponding rounded-up median results obtained in the total breast cancer population.RESULTS: A positive test result for both MUC1 IgG and IgM antibodies in pretreatment serum was associated with a significant benefit in disease-specific survival in stage I and II (P = .0116) breast cancer patients. Positive IgG and IgM MUC1 antibody levels had significant additional prognostic value to stage (P = .0437) in multivariate analysis. Disease-free survival probability did not differ significantly. However, stage II patients who tested positive for MUC1 IgG and IgM antibody and who relapsed had predominantly local recurrences or contralateral disease, as opposed to recurrences at distant sites in the patients with a negative humoral response (P = .026).CONCLUSION: Early breast cancer patients with a natural humoral response to MUC1 have a higher probability of freedom from distant failure and a better disease-specific survival. MUC1 antibodies may control hematogenic tumor dissemination and outgrowth by aiding the destruction of circulating or seeded MUC1-expressing tumor cells. Vaccination of breast cancer patients with MUC1-derived (glyco)peptides in an adjuvant setting may favorably influence the outcome of disease.

scholarly journals Changes in physical activity behavior and C-reactive protein in breast cancer patients

2018 ◽  
Vol 52 (7) ◽  
pp. 545-551 ◽  
Author(s):  
Catherine M Sabiston ◽  
Carsten Wrosch ◽  
Andrée L Castonguay ◽  
Benjamin D Sylvester
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Cancer Patients ◽  
Physical Activity Behavior ◽  
Breast Cancer Patients ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Activity Behavior

Effect of an adjuvant breast cancer vaccine on disease-specific survival of breast cancer patients with depressed lymphocyte immunity.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3087-3087
Author(s):  
Robert Lange Elliott ◽  
Jonathan F. Head
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cell Vaccine ◽  
Disease Specific Survival ◽  
Breast Cancer Patients ◽  
Adjuvant Setting ◽  
Whole Cell ◽  
Historic Control ◽  
Lymphocyte Immunity ◽  
Disease Specific

3087 Background: Breast cancer patients were vaccinated in the adjuvant setting with an autologous, allogeneic whole cell vaccine to evaluate the effect on host lymphocyte immunity and disease-specific survival. Methods: We began preparing whole cell preparations for a vaccine study in 1995. Stage I and II breast cancer patients had host lymphocyte immunity against tumors associated antigens evaluated before and after vaccination. Those patients with depressed immunity, determined by a lymphocyte blastogenesis assay (LBA), were offered the whole cell vaccine. Patients were given six intradermal injections (three weekly followed by three monthly). Ten weeks after the last injection the LBA was repeated. Thirty-seven patients were vaccinated in the adjuvant setting with the whole cell autologous, allogeneic vaccine. Results: The vaccine was well tolerated with no severe toxicities. Some patients experienced slight pain and swelling at the injection site and slight chills and fever. The vaccinated patients had a mean follow-up of 12.7 years with mean follow-up of 8.9 and 9.2 years for the patients with normal and depressed immunity, respectively, in the historic control. The 10-year survival was 95% (20 of 21 patients) in the normal immunity historic control, 59% (33 of 56 patients) in the depressed immunity historic control and 89% (33 of 37 patients) in the patients with depressed immunity that were vaccinated in the present clinical trial. Conclusions: The disease-specific survival of the vaccinated patients with depressed immunity in this trial is significantly greater than that of the historic controls of unvaccinated patients with depressed immunity to their tumor associated antigens. This study confirms the importance of maintaining good host lymphocyte immunity after completion of standard therapy and validates the value of cancer immunotherapy in the adjuvant setting.

MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting

2014 ◽  
Vol 210 (8) ◽  
pp. 494-500 ◽  
Author(s):  
Young Wha Koh ◽  
Hee Jin Lee ◽  
Jin-Hee Ahn ◽  
Jong Won Lee ◽  
Gyungyub Gong
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Disease Specific Survival ◽  
Breast Cancer Patients ◽  
Disease Specific
Sign in / Sign up

Export Citation Format

Share Document